Differentiating pulmonary hypertension associated with protein kinase inhibitors. [PDF]
Pulm Circ, 2022 Protein kinase inhibitors (PKIs) have been implicated in pulmonary vascular toxicities including risk factors for at least three of the five World Health Organization groups of pulmonary hypertension (PH).
Jacobs JA, Jahangir E, Ryan JJ.
europepmc +2 more sources
Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors. [PDF]
Molecules, 2023 Xerxa E, Laufkötter O, Bajorath J.
europepmc +1 more source
Novel Serine-Arginine Protein Kinase Inhibitors for Treating Cancer. [PDF]
ACS Med Chem Lett, 2023 Sabnis RW.
europepmc +1 more source
Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. [PDF]
Cancers (Basel), 2023 Viganò M +5 more
europepmc +1 more source
Critical analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany. [PDF]
Naunyn Schmiedebergs Arch Pharmacol, 2023 Obst CS, Seifert R.
europepmc +1 more source
Data sets of human and mouse protein kinase inhibitors with curated activity data including covalent inhibitors. [PDF]
Future Sci OA, 2023 Xerxa E, Bajorath J.
europepmc +1 more source
Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID. [PDF]
Arch Microbiol, 2023 Narayanan J +6 more
europepmc +1 more source
Editorial: The molecular mechanisms and therapeutic implications of protein kinase inhibitors in cancer therapy. [PDF]
Front Med (Lausanne)Sun YH +4 more
europepmc +1 more source
Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. [PDF]
Int J Mol Sci, 2022 Grela-Wojewoda A +4 more
europepmc +1 more source
Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management. [PDF]
Int J Mol Sci, 2022 Filippone A +10 more
europepmc +1 more source